Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review

Lenvatinib plus transarterial chemoembolization (TACE)have become the first choice for patients with hepatocellular carcinoma (HCC) that are unsuitable for TACE. Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results. However, Lenvatinib plus TACE a...

全面介紹

書目詳細資料

Principais autores:	Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2022-09-01
叢編:	Frontiers in Oncology
主題:	lenvatinib transarterial chemoembolization immune checkpoint programmed death factor 1 inhibitors immune checkpoint inhibitors unresectable hepatocellular carcinoma
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2022.980214/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!